Calcibon D

Quick links to important sections

Calcibon D

Method of action: Vitamins

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Calcibon D

Property Description
Active Ingredients Calcium Citrate and Dihydrotachysterol (DHT)
Form Tablet or Oral Liquid
Pharmacological Class Antihypocalcemic Agent, Vitamin and Mineral Combination
Common Use Supporting bone density and regulating blood calcium
Origin Combination of a calcium salt and a synthetic Vitamin D analog

Calcibon D is an orally administered combination medication classified as a Vitamin and Mineral Combination and an Antihypocalcemic Agent. This preparation is formulated to provide comprehensive support for mineral homeostasis, which is vital for skeletal and systemic health. Clinical application involves agents that combine mineral supply with high absorption capabilities to achieve therapeutic efficacy in calcium management.


What Type of Preparation is Calcibon D?

Calcibon D is formally identified as a combination product that manages the availability of calcium. Its components place it within the Antihypocalcemic Agents class, which are substances used to prevent or correct low levels of calcium in the blood. The medicine is supplied in common oral dosage forms, such as the Tablet or an Oral Liquid. The combination's use of Calcium Citrate is utilized for target patient groups due to its acid-independent absorption profile.


Composition: Calcium Citrate and Synthetic Dihydrotachysterol

The active ingredients are Calcium Citrate and Dihydrotachysterol (DHT). Calcium Citrate is utilized as a source of elemental calcium, offering advantages over some other calcium salts, such as high absorption regardless of stomach acidity. The second component, Dihydrotachysterol, is a synthetic Vitamin D analog. This analog provides a potentially faster onset of action and greater control over mineral levels compared to unactivated natural Vitamin D forms.


General Purpose and Action of Calcibon D

The general purpose of Calcibon D is to reliably support and maintain bone density and stable blood calcium levels. The formulation achieves this by supplying necessary calcium and employing Dihydrotachysterol to optimize the body's management of that mineral. Essentially, Calcibon D acts as a Blood Calcium Regulator, ensuring that the mineral supplied is absorbed and utilized effectively to reinforce the skeletal matrix and sustain vital physiological processes.

Regulatory References

  1. combination medication
  2. Vitamin and Mineral Combination
  3. Antihypocalcemic Agent
  4. Antihypocalcemic Agents
  5. Tablet
  6. Oral Liquid
  7. Calcium Citrate
  8. acid-independent absorption profile
  9. bone density
  10. blood calcium levels
  11. Blood Calcium Regulator

What side effects are possible with Calcibon D?

Possible Side Effects and Safety Information

The safety profile of Calcibon D, which combines Calcium Citrate and Dihydrotachysterol (DHT), is defined primarily by the potential for elevated mineral levels. Adverse reactions are classified by official regulatory documents based on the systems affected and the frequency of occurrence.


Officially Documented Adverse Reactions

The most common and significant adverse reaction is hypercalcemia (excessive calcium in the blood), a dose-related effect of the DHT component, and hypercalciuria (excessive calcium in the urine). These are classified under Metabolism and Nutrition Disorders and Renal and Urinary Disorders, respectively. Other common adverse reactions affecting the Gastrointestinal Disorders system include nausea, vomiting, and constipation.

Classification Examples of Adverse Reactions
Common (Dose-Related) Hypercalcemia, Hypercalciuria, Nausea, Constipation
Uncommon Headache, Dry mouth

Serious Safety Considerations

Official regulatory labeling documents serious adverse reactions associated with prolonged, uncorrected elevations of calcium and phosphate levels. These include Nephrocalcinosis (calcification of kidney tissue) and Ectopic Calcification (calcification in soft tissues). The risk of developing these complications is specifically tied to long-term exposure and sustained hypercalcemia.

Safety constraints restrict the use of Calcibon D in individuals with pre-existing Hypercalcemia, known Vitamin D Toxicity, or evidence of Ectopic Calcification. Patients with Impaired Renal Function are identified as having a significantly increased risk of hypercalcemia and its associated complications, a specific safety note defined in official documents.

Overdose and Emergency Response

Calcibon D overdose is defined by the regulatory-documented development of hypercalcemia (excessive blood calcium) resulting from the combination of Calcium Citrate and the Vitamin D analog Dihydrotachysterol. This condition drives the entire spectrum of officially documented overdose manifestations.

Early signs listed in prescribing information include non-specific symptoms such as polyuria, polydipsia, nausea, vomiting, anorexia, headache, and generalized weakness. Laboratory findings typically show elevated serum calcium and urinary calcium (Hypercalciuria).


Overdose Risk & Outcomes Emergency Action Required
Severe Systemic Toxicity: Overdose can lead to serious, life-threatening outcomes, including cardiac arrhythmias, hypertension, and irreversible renal impairment (nephrocalcinosis). Mental status changes, such as confusion or stupor, may also be present. Seek immediate medical attention for any suspected overdose. Emergency hospitalization is required for severe hypercalcemia due to the risk of cardiac and renal damage.
Antidote & Management: Regulatory documents confirm no specific antidote is known. Management involves the immediate and permanent discontinuation of Calcibon D and initiation of symptomatic and supportive treatment, including close monitoring of serum calcium and renal function. Patients with pre-existing renal impairment are at a higher risk for severe overdose complications.

Therapeutic Uses of Calcibon D

Calcibon D is commonly used to manage mineral homeostasis, addressing conditions where the body struggles to maintain stable calcium levels and bone structure. The active components are considered relevant for therapeutic management across several key domains.

Therapeutic Scope and Benefits

This medication is generally applied across conditions presenting with significant symptomatic burden related to demineralization, such as Osteoporosis, Osteomalacia, Rickets, and Hypoparathyroidism. It also supports the management of specific bone disorders like Renal Osteodystrophy.

A key therapeutic focus involves managing the disruptive manifestations of Neuromuscular Hyperexcitability, which include persistent muscle cramps, spasms, and sensory disturbances like tingling or numbness. This application helps maintain a sense of stability when symptoms are more noticeable, supporting general well-being during symptomatic phases.

“Managing calcium levels is relevant for easing symptoms related to muscle and nerve discomfort.”

In these contexts, Calcibon D plays a role in managing the stability of blood calcium, which contributes to improved day-to-day comfort during symptomatic periods.


Quick Fact: Managing Neuromuscular Symptoms

The medication is commonly used to help with clusters of symptoms related to low plasma calcium, which create noticeable physiological strain on the muscles and nervous system.

Eligibility and Restrictions for Use

Who Can and Cannot Use Calcibon D?

The official eligibility profile for Calcibon D (Calcium Citrate and Dihydrotachysterol) is strictly defined by regulatory contraindications and population restrictions based on official prescribing information.


Absolute Contraindications

Use of Calcibon D is strictly prohibited in patients with certain pre-existing metabolic conditions:

  • Hypercalcemia (abnormally high serum calcium levels).
  • Hypervitaminosis D (Vitamin D toxicity).
  • Known Hypersensitivity to the active substances or any excipient.

Restricted-Use Populations

Eligibility is limited or conditional for the following groups:

  • Pregnancy and Lactation: Use during pregnancy (Category C for DHT) is allowed only if the potential benefit outweighs the potential risk. Caution is required during breastfeeding as excretion into human milk is not known.
  • Age-Group: The medication is primarily intended for Adults and Older Adults. It is generally not recommended for the routine use in the general pediatric population (children and adolescents).
  • Renal Status: Patients with a history of renal stones (nephrolithiasis) or Severe Renal Impairment are restricted and require careful clinical monitoring.

The medicine is otherwise permitted for adults needing management of mineral disorders, such as Hypoparathyroidism and Renal Osteodystrophy, as documented in official labeling.

What should I know about interactions with other medicines?

The official interaction profile for Calcibon D (Calcium Citrate and Dihydrotachysterol) is defined by the risks associated with its mineral and synthetic Vitamin D components, as documented in regulatory prescribing information. The structure is based on pharmacokinetic and pharmacodynamic classification.

Interaction Scope

Property Description
Medicinal product categories with documented interactions: Vitamin D Analogs, Cardiac Glycosides, Thiazide Diuretics, Bisphosphonates, Tetracycline Antibiotics, and Fluoroquinolone Antibiotics
Mechanistic basis of interactions (only if stated in label): Additive effects (hypercalcemia risk), absorption interference (chelation/binding by calcium), and CYP450 3A4 inhibition (by Grapefruit)
Timing-based interaction rules (if applicable): Mandatory separation is required for Bisphosphonates (e.g., 30–60 minutes or more) and Tetracycline/Fluoroquinolone antibiotics (e.g., several hours) to prevent a reduction in antibiotic exposure.
Population-specific interaction notes (if applicable): Interaction severity or outcomes may be altered in patients with documented renal dysfunction or hepatic impairment.
Interaction-related restrictions: Co-administration is contraindicated with other Vitamin D analogs and metabolites due to the risk of severe additive hypercalcemia.

Official Interaction Statements:

  • The co-administration of the Dihydrotachysterol component with other Vitamin D analogs or metabolites is contraindicated due to the potential for an additive effect leading to severe hypercalcemia.
  • Calcium Citrate can bind to certain medicines, resulting in a reduction of exposure for drugs like Tetracycline and Fluoroquinolone antibiotics, which requires a mandatory separation of administration time.
  • Thiazide diuretics and Cardiac Glycosides are documented to present a pharmacodynamic interaction, either by increasing the risk of hypercalcemia (Thiazides) or potentially exacerbating arrhythmias (Cardiac Glycosides).

Mechanism of Action

Calcibon D contains calcium and cholecalciferol (vitamin D3). The calcium component acts as a direct cation substrate, modulating physiological processes via its role as a ubiquitous second messenger. Following intestinal absorption, calcium ions ( Ca^2+) enter the systemic circulation, increasing the plasma concentration. Ca^2+ is then incorporated into the crystalline structure of the bone matrix via the activity of osteoblasts, or it engages in cellular signaling, transmembrane transport, and enzyme cofactor functions across numerous cell types.

The cholecalciferol component is a secosteroid that functions as a prohormone. It is first metabolized in the liver to calcifediol (25-hydroxyvitamin D3) by the enzyme 25-hydroxylase. Calcifediol then undergoes a second hydroxylation in the kidney by 1-alpha-hydroxylase ( CYP27B1) to form the biologically active metabolite, calcitriol (1,25-dihydroxyvitamin D3).

Calcitriol acts as a transcriptional agonist by binding to the intracellular Vitamin D Receptor (VDR), a nuclear receptor. This ligand-receptor complex heterodimerizes with the Retinoid X Receptor (RXR) and translocates to the nucleus, where it binds to specific Vitamin D Response Elements (VDREs) on target gene promoters. This genomic action selectively modulates the transcription of genes encoding proteins that regulate calcium and phosphate metabolism. This includes increasing the expression of the apical calcium channel TRPV6 and the calcium-binding protein Calbindin-D9K in the intestinal epithelium. The downstream physiological cascade involves increased luminal Ca^2+ and phosphate absorption, coupled with modulation of renal tubular reabsorption and parathyroid gland activity, leading to systemic maintenance of calcium and phosphate plasma concentrations.

Dosage and Administration Information

The use of Calcibon D, an oral combination of Calcium Citrate and Dihydrotachysterol (DHT), follows a defined administration protocol. The medication is supplied in oral forms, such as the tablet or liquid solution, and is taken once daily.

Official Dosing Regimens

The dosage is not fixed and must be highly individualized and periodically reevaluated based on the patient's clinical response. The overall regimen is characterized by two distinct phases, beginning with a short-term, higher Initial Phase dose, typically ranging from 0.8 mg to 2.4 mg of DHT daily for several days. This is followed by a reduced, long-term Maintenance Phase dose, generally ranging from 0.2 mg to 1.0 mg daily for adults with conditions like hypoparathyroidism. Specific lower dosage ranges are provided for infants and children.

Procedural Administration Conditions

A fundamental condition for use is the required mandatory laboratory monitoring of serum calcium levels, which must be maintained within the desired therapeutic range. During the initial titration of the dose, blood calcium must be checked frequently, often 1 to 2 times per week. Once a stable dose is achieved, the frequency of monitoring is reduced to approximately once a month. Dose adjustments are performed conservatively, generally at intervals of four to eight weeks, due to the drug's extended effect. The medication can be administered with or without food.

Recent Clinical Evidence

Calcibon D: Recent Clinical Evidence

Clinical Role in Bone Health

Research has consistently examined the role of combined calcium (specifically calcium carbonate) and Vitamin D3 (cholecalciferol) supplementation, such as in Calcibon D, primarily for skeletal health. Extensive meta-analyses and randomized controlled trials (RCTs) generally support the use of this combination in certain high-risk populations, particularly older adults and postmenopausal women, to maintain bone health.

Studies frequently assess key outcomes related to bone density and fracture risk:

  • Fracture Risk: Combined supplementation has been associated with a potential reduction in the relative risk of hip fractures and non-vertebral fractures in some analyses, though results can vary across different study designs and populations.
  • Bone Mineral Density (BMD): Research often focuses on whether the combination affects BMD at the hip and lumbar spine. While some trials suggest a positive influence on BMD, other systematic reviews focusing on healthy adults or premenopausal women have concluded that the evidence remains inconclusive.

Special Focus Areas

Vitamin D Status: Clinical trials have demonstrated that Vitamin D3 supplementation is effective at increasing and maintaining circulating levels of 25-hydroxyvitamin D (25(OH)D) in individuals who are deficient or insufficient. Achieving adequate vitamin D status is essential, as the vitamin plays a critical role in facilitating the intestinal absorption of calcium.

Safety and Tolerability: The safety profile is continuously evaluated. While the combination is generally observed to be well tolerated in studies, research continues to explore potential associations between calcium supplements and certain outcomes, such as cardiovascular events, although evidence remains mixed. Patients should always discuss their individual risk factors and needs with a healthcare provider.

Frequently Asked Questions (FAQ)

Common questions about Calcibon D (FAQ)


Q: What is the main difference between Calcibon D and other Vitamin D pills?

A: Calcibon D contains Dihydrotachysterol (DHT), which is a synthetic Vitamin D analog. DHT is described as an active form of Vitamin D, which means it bypasses the need for the final activation step in the kidney. This is a point of distinction from unactivated natural Vitamin D (like cholecalciferol or D3) found in many common supplements.


Q: Can Calcibon D be taken by people who are lactose intolerant?

A: Official information for Dihydrotachysterol products indicates that lactose is often included as an inactive ingredient in the tablets. Individuals with lactose intolerance are advised to check the inactive ingredients on the product label or consult the official regulatory documents for the precise formulation used.


Q: How quickly does Calcibon D start to work?

A: Dihydrotachysterol is generally described in official labeling as a faster-acting agent compared to high doses of standard, unactivated Vitamin D. The persistent effect of the medication requires that any dosage adjustments be made conservatively, often over a period of several weeks, to ensure mineral levels remain stable.


Q: Does Calcibon D affect sleep or cause insomnia?

A: Insomnia or sleep disturbance is not typically listed as a common adverse reaction in official product information. However, high doses of the medication can lead to hypercalcemia (excessive calcium in the blood). Early signs of severe hypercalcemia can include central nervous system disturbances such as confusion.


Q: Is Calcibon D considered a prescription drug or an over-the-counter supplement in some places?

A: The Dihydrotachysterol component is classified in U.S. regulatory documents as a substance requiring a prescription. Based on the classification of the Dihydrotachysterol component in U.S. regulatory documents, Calcibon D is typically distributed as a prescription medication.


Q: Does Calcibon D cause weight gain or loss?

-A: Weight loss and loss of appetite are documented in official safety information as early symptoms associated with excessive calcium levels, or hypercalcemia. Hypercalcemia is the most significant adverse reaction associated with this medication, and these are documented symptoms to be aware of.


Q: Is Calcibon D safe for people with thyroid problems?

A: Official documentation indicates that Calcibon D is specifically used for managing mineral disorders such as hypoparathyroidism, which is a condition involving the parathyroid glands (located near the thyroid). The medication is not generally indicated for common thyroid issues like hyper- or hypothyroidism.


Q: Can I drink coffee or tea when taking Calcibon D?

A: Regulatory documents do not specifically mention interactions with coffee or tea. However, it is noted that foods high in oxalic acid (found in spinach and rhubarb) or phytic acid (found in bran and whole grains) may decrease the absorption of the calcium component.


Q: Can Calcibon D be taken with iron supplements?

A: The calcium component of Calcibon D is known to interfere with and decrease the absorption of various other minerals and medications. Due to the potential for the calcium component to interfere with the absorption of other minerals, separation of administration time is often advised for mineral supplements.


Q: What are the known interactions with antacids or acid-reducing drugs?

A: Official drug interaction profiles indicate that patients are cautioned against using certain antacids, such as those containing magnesium or high amounts of calcium. These combinations may lead to excessive calcium levels or other complications.


Q: Can Calcibon D make me feel tired or drowsy?

A: Drowsiness is not typically listed as a common adverse reaction. However, official information lists weakness, fatigue, and somnolence (drowsiness) as potential early symptoms associated with developing excessive calcium levels (hypercalcemia).


Q: What should I do if I get a rash after taking Calcibon D?

A: A rash is not listed as a common adverse reaction. Signs of a hypersensitivity reaction, such as a rash or swelling, are classified as serious adverse events that require immediate medical attention according to official safety information.


Q: Does Calcibon D contain any common allergens like gluten or soy?

A: Inactive ingredient lists for Dihydrotachysterol tablets often include substances like lactose and starch. Information regarding specific allergens like gluten or soy may vary between manufacturers; therefore, checking the inactive ingredient list on the product label is necessary.


Q: What does official guidance say about driving after taking Calcibon D?

A: Official guidance does not prohibit driving or operating machinery. However, symptoms of high calcium levels, such as somnolence (drowsiness) and vertigo (dizziness), are potential adverse effects. Individuals should be aware of these potential effects, as they may impair the ability to safely drive or operate machinery.


Q: Can Calcibon D cause changes in mood or anxiety?

A: Changes in mood or anxiety are not common direct adverse effects. However, official regulatory documents indicate that late signs of overdose leading to excessively high calcium levels can include mood changes or mental confusion.

How should Calcibon D be stored and disposed of?

Storage and Disposal Requirements for Calcibon D

The following conditions for storing and disposing of Calcibon D (Calcium Citrate and Dihydrotachysterol) are mandated by official regulatory documents.


Storage and Handling Rules

Requirement Official Condition
Temperature Store at room temperature, not above 30 C (86 F). Do not refrigerate or freeze.
Protection Keep the medicine out of the sight and reach of children for safety. Must be protected from light and moisture to ensure stability.
Packaging Store in the original container and ensure the container remains tightly closed at all times.

Disposal Instructions

Unused or expired Calcibon D should be disposed of according to official regulatory procedures. The preferred method is utilizing an authorized drug take-back program. The product must not be flushed down the toilet or discarded into wastewater systems. If a take-back option is unavailable, the medicine should be mixed with an undesirable substance, placed in a sealed bag, and discarded with household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Calcibon D found in:

A-Z Index: